SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVR and ONLY ADVR

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire5/23/2005 8:17:42 PM
   of 278
 
ALERT ..ADVR Further Expands Its Patent Portfolio
Monday May 23, 7:00 am ET
The Company is Awarded Its Seventeenth Patent

biz.yahoo.com
YONKERS, N.Y.--(BUSINESS WIRE)--May 23, 2005--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) announced today that the patent office in China has granted the Company patent #ZL 00811493.5 entitled "Preparation of a Therapeutic Composition" for AVR118. The patent describes the composition of AVR118 and methods of manufacturing it.
"Developing a strong worldwide intellectual property estate is critical in the field of biotechnology," said Dr. Elma S. Hawkins, President and CEO of Advanced Viral Research Corp. "This is our second patent granted in China for AVR118, thereby providing additional protection for our flagship product."

Currently, ADVR is engaged in a Phase II, multi-center, randomized, double-blind United States study designed to evaluate the effect of a 4.0 ml dose of AVR118 administered to patients with systemic symptoms related to advanced cancers who are not candidates for, or who do not wish to receive, chemotherapy.

ADVR's AVR118 represents a biopolymer that possesses novel immunomodulatory activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus, and to dampen aberrant autoimmune-type inflammatory responses, such as those which occur in patients with rheumatoid arthritis.

The Phase I/II clinical trial of AVR118 in AIDS patients, which was conducted in Israel, concluded that AVR118 continues to demonstrate evidence of unique patient benefits, a favorable safety profile, and no apparent drug-related adverse events. Unique patient benefits included weight gain, mood improvement, decrease in fatigue, and increase in ability to perform everyday tasks.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext